SK1492004A3 - Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines - Google Patents

Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines Download PDF

Info

Publication number
SK1492004A3
SK1492004A3 SK149-2004A SK1492004A SK1492004A3 SK 1492004 A3 SK1492004 A3 SK 1492004A3 SK 1492004 A SK1492004 A SK 1492004A SK 1492004 A3 SK1492004 A3 SK 1492004A3
Authority
SK
Slovakia
Prior art keywords
fluorophenyl
substituted
unsubstituted
dihydro
pyrazolo
Prior art date
Application number
SK149-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Matthew John Laufersweiler
Michael Phillip Clark
Jane Far-Jine Djung
Adam Golebiowski
Biswanath De
Todd Andrew Brugel
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of SK1492004A3 publication Critical patent/SK1492004A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SK149-2004A 2001-09-20 2002-09-20 Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines SK1492004A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32362501P 2001-09-20 2001-09-20
PCT/US2002/030133 WO2003024973A1 (en) 2001-09-20 2002-09-20 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Publications (1)

Publication Number Publication Date
SK1492004A3 true SK1492004A3 (en) 2004-11-03

Family

ID=23259997

Family Applications (3)

Application Number Title Priority Date Filing Date
SK150-2004A SK1502004A3 (en) 2001-09-20 2002-09-20 6,7-Dihydro-5H-pyrazolo[1,2-a] pyrazol-1-ones regulating inflammatory cytokines
SK148-2004A SK1482004A3 (en) 2001-09-20 2002-09-20 Compounds which inhibit the release of inflammatory cytokines
SK149-2004A SK1492004A3 (en) 2001-09-20 2002-09-20 Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SK150-2004A SK1502004A3 (en) 2001-09-20 2002-09-20 6,7-Dihydro-5H-pyrazolo[1,2-a] pyrazol-1-ones regulating inflammatory cytokines
SK148-2004A SK1482004A3 (en) 2001-09-20 2002-09-20 Compounds which inhibit the release of inflammatory cytokines

Country Status (33)

Country Link
US (2) US6566357B1 (ru)
EP (3) EP1427732B1 (ru)
JP (3) JP2005504082A (ru)
KR (4) KR20040035837A (ru)
CN (3) CN1249066C (ru)
AR (3) AR037502A1 (ru)
AT (3) ATE287887T1 (ru)
AU (2) AU2002327690B2 (ru)
BR (3) BR0212716A (ru)
CA (3) CA2461073A1 (ru)
CO (3) CO5560589A2 (ru)
CY (1) CY1106398T1 (ru)
CZ (3) CZ2004361A3 (ru)
DE (3) DE60218704T2 (ru)
DK (2) DK1427732T3 (ru)
EG (2) EG24413A (ru)
ES (3) ES2282459T3 (ru)
HK (2) HK1071366A1 (ru)
HU (3) HUP0500752A2 (ru)
IL (3) IL160682A0 (ru)
MA (3) MA27066A1 (ru)
MX (3) MXPA04002570A (ru)
MY (2) MY129329A (ru)
NO (2) NO20041594L (ru)
NZ (3) NZ531123A (ru)
PE (3) PE20030446A1 (ru)
PL (3) PL370351A1 (ru)
PT (3) PT1427728E (ru)
RU (3) RU2278864C2 (ru)
SA (1) SA03230529B1 (ru)
SK (3) SK1502004A3 (ru)
WO (3) WO2003024970A1 (ru)
ZA (3) ZA200401260B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849627B2 (en) 2001-09-20 2005-02-01 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7087615B2 (en) 2001-09-20 2006-08-08 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7473695B2 (en) 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
US6677337B2 (en) * 2002-03-19 2004-01-13 The Procter & Gamble Company 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
CA2497007A1 (en) * 2002-09-09 2004-03-18 Amgen Inc. 1, 4, 5-substituted 1, 2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivatives s tnf-alpha and interleukin lowering agents for the treatment of inflammations
WO2004087696A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Pirazolidin-1,2-dicarbonsaüre-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US7482356B2 (en) * 2003-11-10 2009-01-27 The Procter & Gamble Company Bicyclic pyrazolone cytokine inhibitors
MY144307A (en) * 2006-04-18 2011-08-29 Abbott Lab Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
PL2432767T3 (pl) * 2009-05-19 2013-11-29 Dow Agrosciences Llc Związki i sposoby zwalczania grzybów
CN107636366B (zh) 2015-06-15 2021-03-12 卡明斯公司 燃烧室弹性装置
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
CN107033090B (zh) * 2017-05-16 2019-05-07 无锡捷化医药科技有限公司 一种1,2,3,4-四氢噌啉的制备方法
RU2721684C1 (ru) * 2019-09-06 2020-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" Метил 2,3,8-триоксо-4-фенилтетрагидро-6Н-пиразоло[1,2-а]пирроло[2,3-c]пиразол-9а(1Н)-карбоксилаты
WO2023076133A1 (en) * 2021-10-27 2023-05-04 Merck Sharp & Dohme Llc Spirotricycle ripk1 inhibitors and methods of uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054291A (ru) * 1963-02-26
GB1124982A (en) * 1965-02-09 1968-08-21 Lepetit Spa Diazabicyclo octanes and derivatives thereof
CH529153A (fr) 1969-10-27 1972-10-15 Lepetit Spa Procédé de préparation de pyrazolo (1,2-b) phtalazine-1,5 (10H)-diones
US5358924A (en) * 1991-03-21 1994-10-25 Bayer Aktiengesellschaft 3-hydroxy-4-aryl-5-oxo-pyrozoline derivatives, compositions and use
PT1481970E (pt) * 1999-09-07 2006-07-31 Syngenta Participations Ag Novos herbicidas
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Also Published As

Publication number Publication date
CZ2004358A3 (cs) 2004-07-14
DK1427728T3 (da) 2007-07-09
AR037237A1 (es) 2004-11-03
HUP0402500A2 (hu) 2005-03-29
PT1427732E (pt) 2006-12-29
HUP0402500A3 (en) 2008-10-28
ATE332901T1 (de) 2006-08-15
MA27066A1 (fr) 2004-12-20
AU2002334641B2 (en) 2007-03-29
PE20030446A1 (es) 2003-07-21
BR0212905A (pt) 2004-10-13
BR0212673A (pt) 2004-08-24
NZ531063A (en) 2007-08-31
ZA200401403B (en) 2004-08-30
CA2461073A1 (en) 2003-03-27
DE60213108T2 (de) 2007-02-08
EP1427727A1 (en) 2004-06-16
ZA200401260B (en) 2004-08-30
CN1555375A (zh) 2004-12-15
PE20030474A1 (es) 2003-07-22
CA2461071A1 (en) 2003-03-27
CN1556811A (zh) 2004-12-22
MA27064A1 (fr) 2004-12-20
PL370362A1 (en) 2005-05-16
DE60218704D1 (de) 2007-04-19
CA2461072A1 (en) 2003-03-27
ATE287887T1 (de) 2005-02-15
NZ531122A (en) 2005-09-30
DE60202782T2 (de) 2006-01-19
WO2003024971A1 (en) 2003-03-27
DE60213108D1 (de) 2006-08-24
IL160741A0 (en) 2004-08-31
MY129069A (en) 2007-03-30
CN1249066C (zh) 2006-04-05
PL370415A1 (en) 2005-05-30
KR100623879B1 (ko) 2006-09-19
NO20041594L (no) 2004-06-21
DE60202782D1 (de) 2005-03-03
US20030105084A1 (en) 2003-06-05
ES2282459T3 (es) 2007-10-16
HK1071565A1 (en) 2005-07-22
JP2005504081A (ja) 2005-02-10
AR037145A1 (es) 2004-10-27
AU2002327690B2 (en) 2006-07-20
CO5560590A2 (es) 2005-09-30
CO5560589A2 (es) 2005-09-30
SK1502004A3 (en) 2004-09-08
KR20040035837A (ko) 2004-04-29
KR100656126B1 (ko) 2006-12-12
EP1427727B1 (en) 2005-01-26
ES2237691T3 (es) 2005-08-01
RU2272040C2 (ru) 2006-03-20
US6566357B1 (en) 2003-05-20
KR20040035835A (ko) 2004-04-29
CY1106398T1 (el) 2011-10-12
HK1071366A1 (en) 2005-07-15
RU2299885C2 (ru) 2007-05-27
PE20030430A1 (es) 2003-06-24
CN1555379A (zh) 2004-12-15
PT1427728E (pt) 2007-05-31
HUP0402378A2 (hu) 2005-02-28
NO20041605L (no) 2004-06-21
EP1427732B1 (en) 2006-07-12
RU2004111803A (ru) 2005-10-10
MXPA04002574A (es) 2004-06-18
US6821971B2 (en) 2004-11-23
CN1250551C (zh) 2006-04-12
PL370351A1 (en) 2005-05-16
ATE356126T1 (de) 2007-03-15
MXPA04002570A (es) 2004-05-31
JP2005504083A (ja) 2005-02-10
IL160682A0 (en) 2004-08-31
DK1427732T3 (da) 2006-10-30
EP1427728A1 (en) 2004-06-16
MXPA04002569A (es) 2004-05-31
CZ2004361A3 (cs) 2004-07-14
RU2004111806A (ru) 2005-03-27
RU2004111805A (ru) 2005-04-10
EP1427732A1 (en) 2004-06-16
BR0212716A (pt) 2004-08-03
HUP0500752A2 (en) 2006-01-30
EP1427728B1 (en) 2007-03-07
IL160742A0 (en) 2004-08-31
EG24413A (en) 2009-05-25
CO5560579A2 (es) 2005-09-30
ES2268154T3 (es) 2007-03-16
MY129329A (en) 2007-03-30
PT1427727E (pt) 2005-06-30
MA27065A1 (fr) 2004-12-20
KR20040035836A (ko) 2004-04-29
JP2005504082A (ja) 2005-02-10
NZ531123A (en) 2006-08-31
HUP0402378A3 (en) 2008-10-28
SA03230529B1 (ar) 2008-06-21
WO2003024970A1 (en) 2003-03-27
CZ2004345A3 (cs) 2004-06-16
DE60218704T2 (de) 2007-11-08
EG24363A (en) 2009-03-04
RU2278864C2 (ru) 2006-06-27
KR20060036125A (ko) 2006-04-27
WO2003024973A1 (en) 2003-03-27
SK1482004A3 (en) 2004-08-03
CN1257905C (zh) 2006-05-31
AR037502A1 (es) 2004-11-17
ZA200401402B (en) 2004-08-27

Similar Documents

Publication Publication Date Title
SK1492004A3 (en) Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7368455B2 (en) 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
AU2002334641A1 (en) Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
AU2002327690A1 (en) 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
PT1465921E (pt) Espirocíclico-6, 7-di-idro-5h-pirazolo[1,2-a] pirazol-1-onas que controlam citocinas inflamatórias
US6849627B2 (en) 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7326714B2 (en) 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure